Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 11/20 | 0.49 |
| ▸ | TYRO3 | Q06418 | 10/20 | 0.49 |
| ▸ | AXL | P30530 | 6/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | GAS6 | Q14393 | 5/20 | 0.40 |
| ▸ | FLT3 | P36888 | 4/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 4/20 | 0.39 |
| ▸ | ULK1 | O75385 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715006 | 0.78 | MERTK (0.50) | MERTKTYRO3GAS6FLT3SYK | |
| SCHEMBL5057521 | 0.76 | AURKA (0.38) | MERTKFLT3 | |
| SCHEMBL29507825 | 0.73 | MERTK (0.46) | MERTKTYRO3GAS6FLT3SYK | |
| SCHEMBL6424706 | 0.73 | KMT2A (0.60) | AXL | |
| SCHEMBL21258189 | 0.73 | ULK1 (0.71) | FLT3ULK1 | |
| SCHEMBL22860693 | 0.72 | MERTK (0.46) | MERTKSYKULK1 | |
| SCHEMBL2622288 | 0.72 | GABBR2 (0.47) | MERTK | |
| SCHEMBL4713140 | 0.71 | GABBR2 (0.46) | MERTK | |
| SCHEMBL4711841 | 0.71 | GABBR2 (0.46) | MERTK | |
| SCHEMBL20365993 | 0.71 | KMT2A (0.38) | MERTKAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549651-B1 | PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS | WARNER LAMBERT CO (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7196090-B2 | Kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| WO-2006038112-A1 | USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS | WARNER-LAMBERT COMPANY LLC (US) | 2006-04-13 | — | — | WO | disclosed |
| EP-1549651-A1 | KINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004011465-A1 | KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040019210-A1 | Kinase inhibitors | CHIVIKAS CONNOLLY CLEO J (US) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019210-A1 | Kinase inhibitors | CDK2, CDK1, CDK4 | MERTK 236/4885TYRO3 262/4885AXL 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.